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Abstract
Background: Patients with peripheral artery disease (PAD) are at increased risk of secondary events, which is
exaggerated in the presence of type 2 diabetes mellitus. Diabetes is associated with a systemic pro-inflammatory
state. We therefore investigated the cumulative impact of PAD and type 2 diabetes on carotid arterial wall
inflammation. As recent data suggest a detrimental role of exogenous insulin on cardiovascular disease, we also
included a group of insulin users.
Results: 18F-fluorodeoxyglucose positron emission tomography with computed tomography (18F-FDG PET/CT)
imaging showed increased carotid arterial wall inflammation, assessed as target-to-background ratio (TBR), in PAD
patients without diabetes (PAD-only: n = 11, 1.97 ± 0.57) compared with matched controls (n = 12, 1.49 ± 0.57;
p = 0.009), with a significant further TBR increase in PAD patients with type 2 diabetes (PAD-DM, n = 23, 2.90 ± 1,
p = 0.033 vs PAD-only). TBR of insulin users (n = 12, 3.31 ± 1.14) was higher compared with patients on oral
medication only (n = 11, 2.44 ± 0.76, p = 0.035), despite comparable PAD severity (Fontaine stages), BMI and CRP.
Multivariate regression analysis showed that Hba1c and plasma insulin levels, but not dose of exogenous insulin,
correlated with TBR.
Conclusions: Concurrent diabetes significantly augments carotid arterial wall inflammation in PAD patients. A
further increase in those requiring insulin was observed, which was associated with diabetes severity, rather
than with the use of exogenous insulin itself.
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Background
Although atherosclerosis is a systemic process, there is
clear heterogeneity in the association between different
risk factors and the vascular beds affected, implying patho-
physiological differences between atherosclerotic cardiovas-
cular disease (CVD) in different arterial regions [1]. In line,
the occurrence of secondary CV events differs between pa-
tients with different primary disease manifestations: 21 %
CV-events in peripheral artery disease (PAD) patients, 15 %
in cerebrovascular disease patients and 15 % in coronary ar-
tery disease (CAD) patients [2]. Moreover, the event rates
increase when there is more than one vascular bed affected,
whereas there is a clear increase in the presence of polyvas-
cular disease in PAD patients (60 %) compared to patients
with cerebrovascular disease (15 %) or CAD (25 %). The
preponderance of diffuse atherosclerotic disease and events
in PAD patients has been partly attributed to a systemic
pro-inflammatory state with increased c-reactive protein
(CRP) levels [3, 4].
Arterial wall 18F-fluordeoxyglucose (18F-FDG) uptake
has been extensively validated as a marker of athero-
genic inflammation. 18F-FDG uptake primarily occurs in
macrophage-rich areas in atherosclerotic plaques [5].
Local measurement of 18F-FDG is strongly associated with
systemic atherosclerotic burden [6], is capable of dissect-
ing symptomatic from asymptomatic lesions [7, 8] and
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finally, predicts future CV events [9]. There is only limited
data on the relation between PAD and arterial wall inflam-
mation, despite evidence of a systemic pro-inflammatory
state in PAD patients and the high rate of events in other
vascular territories.
Furthermore, patients with PAD and concomitant type
2 diabetes are at a two-fold increased risk of cardiovas-
cular death compared with PAD-patients without dia-
betes [10]. Amongst others, this has been suggested to
relate to the pro-inflammatory effects of hyperglycaemia
and/or hyperinsulinemia [11, 12]. It has been speculated
that exogenous insulin use could further augment sys-
temic inflammation and subsequently increase CVD risk,
based on a seemingly independent adverse effects of in-
sulin use on cardiovascular risk [13], combined with inflam-
matory actions of insulin in vitro [14]. However, there is
currently no direct evidence that increased systemic arterial
wall inflammation may be implicated in the cumulative
impact on cardiovascular risk of PAD and type 2 diabetes,
nor has the association between exogenous insulin use and
arterial wall inflammation been previously investigated.
The primary objective of our study is to determine
whether: i) the high burden of polyvascular disease and
systemic inflammation in PAD is reflected in increased
inflammatory activity of the carotid arterial wall and ii)
if concomitant type 2 diabetes augments arterial wall in-
flammation. We also aimed to explore whether such in-
flammatory activity is further influenced by insulin-use.
Therefore, we assessed carotid arterial wall inflammation
in PAD patients with or without type 2 diabetes. Subse-
quently, we compared 18F-FDG uptake between PAD pa-
tients with type 2 diabetes with or without exogenous
insulin in addition to oral antidiabetic drugs.
Methods
Study design and population
We performed a cross-sectional study in a random se-
lection of patients with PAD who visited the outpatient
clinic between August 2014 and March 2015. PAD was
defined as an Ankle-Brachial Index (ABI) <0.9 and/or a
decrease of >0.15 in ABI after a treadmill-test, and the
presence of exertional leg pain or rest pain [15]. Exclu-
sion criteria were type 1 diabetes, presence of tissue loss
(Fontaine stage IV), history of a recent CV-event (i.e.,
myocardial infarction or cerebrovascular event within the
last 6 months) and clinical or biochemical signs of acute
infection (fever or CRP >10 mg/dl). Subjects were divided
in three groups: 1) PAD without diabetes (PAD-only), 2)
PAD with type 2 diabetes using oral antidiabetic drugs
only (NIDDM) or 3) PAD using a combination of oral
antidiabetic drugs and insulin (IDDM). Groups were
matched for age, gender, body mass index (BMI) and
smoking. The study was conducted at the Academic
Medical Center in Amsterdam, the Netherlands. The
study protocol was approved by the institutional review
board of the Academic Medical Center in Amsterdam,
The Netherlands. Written informed consent was obtained
from each participant.
Medical history, biometric and biochemical
measurements
All subjects underwent cardiovascular risk assessment
including risk factors and family history. Medication use
and Fontaine classification [15] were extracted from the
medical history. Physical examination, including weight,
height and blood pressure was performed. Basal fasting
glucose, HbA1c, total cholesterol, HDL and LDL cholesterol,
triglycerides and free fatty acids (FFAs) were assessed in fast-
ing plasma using standard laboratory procedures. Glucose
was determined using finger stick blood glucose measure-
ments, insulin was determined on an Immulite 2000 system
(Diagnostic Products, Los Angeles, CA). C-peptide was
measured by RIA (RIA-coat C-peptide; Byk-Sangtec
Diagnostica, Dietzenbach, Germany). Homeostasis model
assessment (HOMA) index was calculated as a measure for
insulin sensitivity (HOMA= insulin (pmol)/6.945*glucose
(mmol)/22.5).
18F-FDG- PET/CT Imaging
18F-FDG positron emission tomography with computed
tomography (PET/CT) scans of the carotid arteries were
performed on a dedicated scanner (Philips, Best, the
Netherlands). Subjects fasted for at least 6 h before infu-
sion of 100 MBq 18F-FDG. The PET scan was performed
90 min post-infusion, with a low-dose, non-contrast en-
hanced CT for attenuation correction and anatomic co-
registration (slice thickness 3 mm). The scan started at
the meatus acusticus externa and ended at the caudal
side of the heart, including 3 bed positions. Because of
ethical constraints relating to radiation exposure, age
and gender matched healthy controls were selected from
a contemporaneous study using identical imaging proto-
cols and performed on the same scanner.
Image analysis
Images were analyzed with dedicated software (OsiriX,
Geneva, Switzerland; http://www.osirix-viewer.com) by
experienced readers blinded for patient data (SLV, FvdV,
intra- and inter-observer agreement was excellent for FDG
uptake metrics in the arterial wall, with ICCs of >0.94 with
narrow 95 % confidence intervals [16]). In the carotid
arteries, 18F-FDG uptake was assessed in at least five
regions of interest (ROI). From each ROI, the mean
and maximum standardized uptake values (SUVs) were
obtained. The SUV represents the 18F-FDG activity in the
ROI (in kBq/ml), adjusted for the administered 18F-FDG
dose, corrected for decay (in MBq) and divided by body
weight (in kg). Mean and maximum SUVs were averaged
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for each arterial segment (SUVmean and SUVmax). As
previous studies have shown that hyperglycemia lowers
18F-FDG uptake [17], SUV values were corrected for
fasting pre-scan glucose levels as described previously,
normalizing measured glucose levels for an overall popula-
tion average of 5 mmol/L [11]. Background 18F-FDG activ-
ity was measured in the venous blood pool as an average
of at least 5 ROIs.
The glucose-corrected TBR was obtained for both ca-
rotids by normalizing the respective glucose-corrected
SUV values in the arteries for blood pool activity, result-
ing in TBRmean and TBRmax. Three adjoining segments
with the highest TBR were used to calculate the most
diseased segment (TBRmds). For each subject, the artery
with the highest glucose corrected TBR (index vessel)
was used for comparisons.
Statistical analysis
The sample size calculation was guided by previously re-
ported differences in mean maximal TBR between CVD
patients and healthy controls, because insufficient evi-
dence exists regarding the potential cumulative effect of
PAD and type 2 diabetes. The calculations (which are
provided in the Additional file 1: Table S1) yielded a
sample size of 17, and we chose to increase the number
to approximately 30 participants because we anticipated
smaller differences between PAD patients with or with-
out diabetes versus PAD patients and healthy controls.
All data were analysed using Prism version 5.0 (Graph-
Pad software, LaJolla, California) and SPSS version 21.0
(SPSS Inc., Chicago, Illinois). Continuous variables are
expressed as means and standard deviations (SD) or me-
dian and interquartile range (IQR), unless otherwise spe-
cified. Differences in baseline characteristics between the
groups were assessed using t-tests or Mann Whitney U
test depending on distribution for continuous variables,
and Chi-square tests for categorical variables. Differences in
TBR between controls and PAD-only patients, PAD-DM
and PAD-only patients, as well as between PAD-IDDM and
PAD-NIDDM, were assessed with a univariate analysis of
covariance (ANCOVA) to account for age and gender.
Multiple linear regression
Multiple linear regression analysis with backward elimin-
ation was used to disentangle the relative contribution
of cardiovascular risk factors and factors related to dia-
betes to the various glucose-corrected TBR parameters,
both in the overall group and in the subgroup of patients
with diabetes. The initial model included age, gender, BMI,
smoking, systolic blood pressure, TC/HDL-ratio, CRP and
diabetes. In the secondary analysis, which aimed to explore
whether exogenous insulin use independently contributed
to the study outcomes HbA1c and fasting circulating insu-
lin were additionally included as measures of diabetes
regulation. As HbA1c and circulating insulin were non-
normally distributed (Shapiro-Wilk p = 0.020 and p = 0.015
respectively), values were log transformed before entering
them into the model. Backward stepwise elimination
(probability for removal p > 0.1) resulted in the final model,
and variables with a p < 0.05 were considered statistically
significant.
Exploration of associated variables
Pearson or Spearman’s rho correlation coefficients (de-
pending on normal distribution) were calculated to assess
multi-collinearity between explanatory variables. To pro-
vide additional support for any observed relations between
diabetes- and insulin-related variables and arterial wall in-
flammation, Pearson or Spearman’s rho correlation coeffi-
cients (r) were calculated for both glucose and HbA1c, as
well as between c-peptide and exogenous insulin dose and
various TBR-measures and various TBR measures.
Results
Baseline characteristics
Baseline characteristics are summarized in Table 1. We
included 34 PAD patients (age 64 ± 7), 11 of whom had
PAD only (PAD, age 66 ± 6), and 23 had PAD and diabetes
(PAD-DM, age 63 ± 7) and 11 age and gender matched
controls (control, age 63 ± 3). The majority of the PAD pa-
tients had Fontaine stage 2 (a or b). PAD severity was
equally distributed over diabetic and non-diabetic patients
and did not differ between insulin and non-insulin users
(Additional file 1: Table S2). The PAD-DM group consisted
of 11 patients using oral antidiabetic drugs only (PAD-
NIDDM, age 64 ± 7) and 12 patients also using insulin
(PAD-IDDM, age 63 ± 7). As expected, PAD patients had a
worse CV risk profile compared to controls, with higher
BMI, blood pressure and more smokers as well as in-
creased CRP levels. Most PAD subjects used a statin,
and statin use was not different between subjects with
and without diabetes. Anti-hypertensive medication was
more frequently used in subjects with diabetes (medication
use is specified in Additional file 1: Table S3). All PAD sub-
groups were matched for gender Systolic blood pressure,
lipid profile and circulatory markers of inflammation (CRP,
leucocyte count) did not differ between PAD subgroups.
As expected, fasting glucose and HbA1c levels were higher
in the diabetic group (glucose; PAD only: 5.7 ± 0.4, PAD,
DM: 8.0 ± 2.6, p = 0.001. HbA1c; PAD only: 42 ± 6, PAD,
DM: 62 ± 18, p < 0.001). Within the diabetic subjects,
HbA1c and HOMA-IR was significantly higher in insulin
dependent subjects (Hba1c; NIDDM: 51 ± 16, IDDM: 71 ±
15, p = 0.006. HOMA-IR; NIDDM: 3,2[2,9-5,4], IDDM
9,8[5,0-16], p = 0.038). C-peptide was significantly lower in
patients using exogenous insulin.
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Age, years 63 ± 3 64 ± 7 0.322 66 ± 6 63 ± 7 0.243 64 ± 7 63 ± 7 0.781
Gender,%male (n) 64 (7) 64 (21) 0.949 64 (7) 61 (14) 0,616 55 (6) 67 (8) 0.735
BMI, Kg/m2 26 ± 2 29 ± 4 <0.001 29 ± 4 29 ± 4 0,752 30 ± 5 29 ± 3 0.640
Smoking, % active 25 (3) 46 (15) <0.001 50 (5) 44 (10) 0.912 45 (5) 35 (6) 0.692
SBP 136 ± 6 155 ± 19 <0.001 151 ± 16 156 ± 21 0.436 151 ± 19 161 ± 22 0.281
DBP 81 ± 4 81 ± 10 0.886 82 ± 11 81 ± 9 0.785 82 ± 6 80 ± 11 0.526
TotChol, mmol/L 5.7 ± 0.8 4.4 ± 0.9 <0.001 4.8 ± 0.8 4.3 ± 0.9 0.097 4.2 ± 1.3 4.3 ± 0.4 0.807
LDL, mmol/L 3.7 ± 0.6 2.5 ± 0.8 <0.001 2.9 ± 0.7 2.4 ± 0.8 0.109 2.4 ± 1.1 2.4 ± 0.5 0.952
HDL, mmol/L 1.4 ± 0.4 1.2 ± 0.4 0.116 1.4 ± 0.4 1.2 ± 0.3 0.144 1.2 ± 0.3 1.2 ± 0.4 0.102
TG, mmol/L 1.1 [0.7–1.5] 1.3 [0.9–2.0] 0.196 1.1 [0.8–2.1] 1.3 [1.0–2.1] 0.384 1.2 [1.1–1.6] 1.6 [0.9–2.6] 0.525
CRP, mg/dl 1.3 [0.9–2.1] 2.6 [1.4–5.7] 0.038 1.8 [1.4–2.7] 2.9 [1.4–6.4] 0.144 2.9 [1.9–8.1] 2.9 [0.7–6.2] 0.525
Leucocytes, 109/L 6.0 ± 1.4 7.4 ± 2.5 0.083 6.8 ± 2.2 7.7 ± 2.6 0.370 8.0 ± 2.4 7.6 ± 2.5 0.624
Diabetes n/a n/a n/a No Yes n/a Yes Yes n/a
Glucose, mmol/L 5.3 ± 0.4 7.3 ± 2.5 <0.001 5.7 ± 0.4 8.0 ± 2.6 0.001 7.1 ± 1.4 8.9 ± 3.2 0.102
Insulin, pmol/L n/a n/a n/a 89 [49–175] 103 [67–178] 0.464 85 [60–140] 174 [78–300] 0.122
Hba1C
mmol/mol n/a n/a n/a 41 [38–49] 57 [48–82] <0.001 49 [43–57] 78 [57–85] 0.006
% n/a n/a n/a 5.9 [5.6–6.6] 7.4 [6.5–9.7] 6.6 [6.1–7.4] 9.3 [7.4–9.9]
c-peptide, mmol/L n/a n/a n/a 560 [420–970] 670 [550–880] 0.621 800 [660–1110] 565 [355–790] 0.032
HOMA-IR n/a n/a n/a 2.3 [1.3–6.0] 5.1 [3.0–10.4] 0.032 3.2 [2.9–5.4] 9.8 [5.0–16] 0.038
Values are % (n), mean ± SD or median [IQR,] for skewed data. PAD indicates Peripheral artery disease. DM (type 2 diabetes mellitus). NIDDM non-insulin dependent diabetes mellitus, IDDM insulin-dependent diabetes
mellitus, BMI body mass index, SBP systolic blood pressure, SDP diastolic blood pressure, TotChol total cholesterol, LDL low density lipoprotein, HDL high density lipoprotein, TG triglycerides, CRP c-reactive protein,
















Overall, we found significantly elevated 18F-FDG uptake
in PAD patients compared to controls (TBRmean PAD
2.60 ± 1.01 vs Control 1.49 ± 0.57, p = 0.001 data not
shown). In non-diabetic PAD patients, TBRmean was 1.97 ±
0.57, which was still significantly elevated compared with
the non-PAD control cohort (p = 0.009 (ANCOVA adjusted
for age and gender). Compared with non-diabetic PAD pa-
tients, diabetic PAD patients showed an almost 1.5 fold in-
crease in 18F-FDG uptake (PAD-DM; TBRmean: 2.90 ± 1.05,
p = 0.033 adjusted for age and gender). Maximum carotid
uptake and uptake in the Most Diseased Segment (MDS)
showed similar differences (Fig. 1 a-c). Within the diabetic
patients, the increase in TBR was most pronounced in in-
sulin dependent subjects (PAD-IDDM; TBRmean: 3.31 ±
1.14 versus PAD-NIDDM; 2.44 ± 0.76, p = 0.035), with simi-
lar results for TBRmax and TBRmds (Fig. 1 d-f).
Multiple regression analysis
As the PAD cohort had a significantly worse CV risk
profile and elevated CRP levels compared to controls,
we set out to investigate which factors contributed to
the difference in TBR. In the complete cohort of PAD
patients, the presence of diabetes was the only predictor
which remained significantly correlated with glucose-
corrected carotid 18F-FDG uptake after stepwise backward
elimination (Table 2). BMI and systolic blood pressure
reached the p = 0.10 threshold and were retained in the
model, but did not show a significant correlation with
TBR (Table 2).
Multiple regression analysis in the diabetic subgroup
To disentangle the association between exogenous insu-
lin use and disease severity on the one hand, and arterial
wall inflammation on the other, we performed multiple
regression analysis in the PAD-DM group, adding circu-
lating insulin and Hba1c as explanatory variables. Within
this group, Hba1c and circulating levels of insulin were
significantly correlated with whole carotid 18F-FDG up-
take (Table 3).
Exploration of associated variables
Next, we assessed factors influencing Hba1c and Insulin
(which did not correlate to each other (r = 0.217, p =
0.387)). As expected, fasting glucose and Hba1c showed
significant correlation to each other (r: 0.601, p = 0.004),
and following, fasting glucose showed significant correl-
ation to carotid arterial wall inflammation (r: 0.845, p <
0.001) (Fig. 2a). On the other hand, although fasting in-
sulin levels correlated with arterial wall inflammation
(Fig. 2b), neither c-peptide levels nor dose of exogenous
Fig. 1 Quantification of 18F-FDG uptake as the target to background
ratio (TBR) in the whole (a, d) carotid arteries, as well as the maximum
TBR (b, e) and TBR in the most diseased segment (MDS) (c, f) revealed
increased uptake in all segments in PAD subjects compared with
healthy controls, and a further increase in PAD subjects with
concomitant Diabetes Mellitus (a-c). Within Diabetic subjects,
insulin dependent subjects (IDDM) had more severe arterial wall
inflammation compared with non-insulin dependent subjects
(NIDDM) (d-f). P values are adjusted for age and gender. *p < 0.05,
**p < 0.01, ***p < 0.001
Table 2 Multiple Linear Regression Analyses with Backward
Elimination to Identify Markers that Predict Carotid Arterial Wall







Diabetes 0.357 0.068–1.455 0.033
BMI 0.320 −0.001–0.169 0.053
Systolic Blood Pressure 0.312 −0.001–0.033 0.062
Glucose-Corrected TBRmax
Diabetes 0.382 0.160–2.006 0.023
BMI 0.311 −0.005–0.221 0.060
Systolic Blood Pressure 0.285 −0.003–0.042 0.086
Glucose-Corrected TBRmds
Diabetes 0.368 0.117–2.104 0.030
BMI 0.304 −0.009–0.234 0.068
Systolic Blood Pressure 0.285 −0.004–0.045 0.090
Whole Carotid glucose Corrected Target-to-Background ratio (TBRmean), maximum
uptake (TBRmax) and Most Diseased Segment (TBRmds) were the response variables.
Explanatory factors comprised Cardiovascular risk factors (age, gender, BMI,
smoking, systolic blood pressure, TC/HDL-ratio, CRP and diabetes) and the
inflammatory marker CRP. Variables were retained in the model when P < 0.10.
Data are standardized coefficient (β) with 95 % confidence intervals (CI)
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insulin were associated with circulating insulin levels
(Additional file 1: Table S4) or with carotid 18F-FDG up-
take (Insulin dose: Fig. 2c, C-peptide: Additional file 1:
Figure S1). This raised the suggestion that association of
the circulating levels of insulin with arterial FDG uptake
is a function of insulin resistance, which was corroborated
by a strong correlation between HOMA-IR and arterial
wall inflammation (Fig. 2d).
Discussion
In the present study, we demonstrate that PAD patients
have elevated carotid arterial 18F-FDG uptake, substanti-
ating the presence of a systemic pro-inflammatory state
in these patients. Concomitant diabetes further augments
the arterial wall inflammation 1.5-fold. Previous studies
led to speculations on a possible independent effect of in-
sulin use on cardiovascular risk. However although we did
find increased carotid 18F-FDG uptake among insulin-
users, this can probably not be explained by direct effects
of exogenous insulin use, since 18F-FDG-uptake was only
positively associated with HbA1c and total plasma insulin
Table 3 Multiple Linear Regression Analyses with Backward
Elimination to Identify Markers that Predict Carotid Arterial Wall







Circulating Insulin 0.541 0.514–1.458 0.001
Hba1c 0.537 1.014–2.903 0.001
Glucose-Corrected TBRmax
Circulating Insulin 0.552 0.550–2.049 0.002
Hba1c 0.477 0.748–3.748 0.006
Glucose-Corrected TBRmds
Circulating Insulin 0.536 0.723–4.007 0.008
Hba1c 0.480 0.501–2.142 0.004
Whole Carotid glucose Corrected Target-to-Background ratio (TBRmean), maximum
uptake (TBRmax) and Most Diseased Segment (TBRmds) were the response variables.
Explanatory factors comprised cardiovascular risk factors (Age, Gender, BMI,
smoking, Systolic Blood Pressure) and factors associated with Diabetes regulation
(Insulin and Hba1c, both log-transformed). Variables were retained in the model
when P < 0.10. Data are standardized coefficient (β) with 95 % confidence
intervals (CI)
Fig. 2 Target to Background ratio (TBRmean) significantly correlated to fasting glucose levels (Correlation coefficient: 0.845, p< 0.001) (a). Fasting insulin
correlated significantly to TBRmean (b) but dose of exogenous insulin did not (Insulin: Correlation coefficient: 0.814, p< 0.001; Exogenous insulin dose:
Correlation coefficient: 0.235, p= 0.486). Insulin resistance, measured by HOMA-IR, stongly associated with TBRmean (Correlation coefficient:, 0.876, p< 0.001)
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concentration but not with exogenous insulin dose. These
data imply a role for hyperglycaemia and/or insulin resist-
ance rather than exogenous insulin use.
PAD, inflammation and secondary events
Our results support the concept that increased systemic
arterial wall inflammation mechanistically links PAD with
the preponderance towards secondary cardiovascular
events [2, 18, 19]. Previous studies showed that increased
CRP levels are associated with an increased CVD risk in
PAD subjects [20–22]. Nevertheless, it has been shown
that CRP alone cannot explain future CV morbidity and
mortality in PAD patients [23, 24], indicating that it is
merely a marker and not a causal factor in CVD risk.
More recently, local inflammatory activity of the arterial
wall, assessed with 18F-FDG uptake, emerged as a predict-
ive marker for future CV-events [9]. FDG arterial wall up-
take occurs predominantly in macrophage rich areas [7],
correlates with plaque macrophage content [8] and is as-
sociated with active culprit lesions [7, 25]. As such, our
finding that PAD patients have significantly increased
TBR in the carotid arteries compared with age and gender
matched controls, suggests that arterial wall inflammation
may be involved in the high burden of polyvascular dis-
ease in PAD patients, emphasized by the fact that coron-
ary events are the major cause of death in this group [2].
In line with previous studies [8, 9], in our multivariate
model, CRP levels did not influence inflammatory activity
of the arterial wall, implying that CRP levels do not dir-
ectly influence arterial wall inflammation in PAD patients.
Factors influencing arterial inflammation in PAD patients
Our finding that PAD and type 2 diabetes have an addi-
tive effect on carotid arterial wall inflammation suggests
that systemic arterial wall inflammation may be impli-
cated in the particularly elevated cardiovascular risk of
patients with this combination. Previous studies reported
increased arterial inflammation in patients with type 2
diabetes [11]. One possible explanation for our finding is
that PAD patients with concomitant diabetes have more
advanced PAD. However, clinical PAD disease severity
assessed with the Fontaine classification did not signifi-
cantly differ between the groups. ABI is of limited value
in comparing PAD severity, because diabetes is known
to falsely elevate ABI values [15]. Several factors other
than PAD disease severity may contribute to the increased
inflammation in patients with PAD and concomitant type
2 diabetes. The impact of hyperglycaemia and insulin re-
sistance on arterial inflammation in humans has been cor-
roborated using PET/CT as surrogate marker [11, 12].
However, data on glucose homeostasis from these studies
are limited to a relation between hyperglycemia and
18F-FDG uptake, and these studies comprised only type
2 diabetes patients who used oral antidiabetic medication.
We elaborated on these findings, by including HbA1c
and (fasting) insulin levels in our analyses. In a multi-
variate model, both circulating insulin and HbA1c were
associated with increased 18F-FDG uptake, proposing a
strong association between diabetic control and arterial
wall inflammation.
In vitro studies and cohort studies prompted questions
on a possible adverse effect of insulin use on cardiovascu-
lar risk [13]. To further elucidate this association, we also
included type 2 diabetes patients using insulin. These pa-
tients were characterized by a 1.5-fold further increase in
18F-FDG uptake compared with type 2 diabetes patients
not using insulin. Given the worse regulation of diabetes
in insulin users (Hba1c in PAD-IDDM 78 mmol/mol ver-
sus 49 mmol/mol in PAD-NIDDM), we cannot discrimin-
ate the role of exogenous insulin use versus worse diabetic
control. However, daily insulin dose did not correlate with
arterial 18F-FDG uptake, whereas plasma insulin concen-
trations and indices of insulin resistance were highly cor-
related with 18F-FDG-uptake. These findings imply that
insulin resistance and hyperglycaemia, rather than the use
of exogenous insulin is associated with inflammatory acti-
vation. In support, a recent analysis in the randomized,
placebo-controlled ACCORD trial also could not substan-
tiate the link between insulin dose used and CV events,
after adjustment for baseline covariates [26].
Limitations
Several limitations need to be taken into account when
interpreting our data. First, previous studies in other
diseases were available to underpin the sample size cal-
culation for the comparison between PAD patients and
controls, but no data were available to determine the
appropriate sample size for the other analyses. As such,
the other analyses may be underpowered and should be
interpreted as merely hypothesis forming. Moreover, the
study design precludes any conclusions on causality of the
observed associations, and the different presence of other
cardiovascular risk factors associated with diabetes and
CVD complicates interpretation of our findings. For ex-
ample hypertension, represented by the higher level of use
of antihypertensive medication was more often present in
the diabetes group, however, treated systolic blood pres-
sure was not significantly associated with arterial inflam-
mation [11]. Thus, our data contribute to a growing body
of evidence highlighting the importance of inflammation
in the adverse CVD risk profile of patients with dia-
betes and highlight the need to understand underlying
pathophysiology.
Second, we did not evaluate arterial wall inflammation
in other territories than the carotid arteries. The carotid
artery has been recommended as a primary readout
vessel to evaluate arterial wall inflammation because it
has been most extensively validated. Thus, we considered
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the carotid artery as an appropriate measure to evaluate
the extent of systemic arterial wall inflammation in PAD
patients [16]. 18F-FDG PET/CT can be excellently repro-
duced across the arterial tree, as published previously
[27]. We did not perform structural measurements of
the carotid arteries (MRI or ultrasound) to assess carotid
atherosclerotic burden. However, Tahara and colleagues
previously established a correlation between carotid intima-
media thickness (c-IMT) and SUV uptake [12] and as out-
lined in the introduction, arterial inflammation has been
extensively confirmed as an independent measure for CVD
risk. Finally, given the cross-sectional design of the current
study, no conclusions can be drawn on the implications of
the observed associations in terms of clinical outcomes.
Although 18F-FDG has been shown to be of value in
assessing cardiovascular risk [9], glucose-corrected TBRs
have not been validated concerning definitive outcomes,
and long term studies are necessary to prove its relation
with CV-events.
Conclusions
In the current study, we show that PAD patients have
significantly increased inflammation in the carotid arter-
ies, which is augmented by the presence of type 2 diabetes.
Given the particularly adverse CVD risk profile of PAD
patients with concomitant diabetes and the growing body
of evidence on the importance of inflammation in both
atherosclerosis and diabetes, our findings suggests that ar-
terial wall inflammation is involved in the adverse CVD
risk profile of these patients. Identification of key media-
tors may aid in more targeted prevention in the future.
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